Acalabrutinib for Mantle Cell Lymphoma

Thomas E Witzig and David Inwards


Mantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma (NHL) characterized by the overexpression of cyclin D1. MCL patients typically live years but experience multiple relapses. Acalabrutinib (Acala) is a novel second generation oral Bruton's tyrosine kinase (BTK) inhibitor approved by the US FDA for relapsed MCL based on a clinical trial demonstrating an overall response rate of 81%. It provides a valuable new treatment option for MCL patients and is now being tested upfront.

  • Submitted January 4, 2019.
  • Revision received March 12, 2019.
  • Accepted March 11, 2019.